Latest news with #HCC
Yahoo
8 hours ago
- Business
- Yahoo
Holyoke Community College announce resignation of Vice President Sharale Mathis
HOLYOKE, Mass. (WWLP) – After leading academic and student affairs at Holyoke Community College for four years, Vice President Sharale Mathis has announced her resignation. Dr. Sharale Mathis served as the vice president for academic and student affairs. In a staffing update, HCC President George Timmons announced the resignation of Mathis, citing the acceptance of a position as President of the Capital and Tunxis campuses within the Connecticut State Community College system. Holyoke Community College to offer free course in AI essentials Mathis began her career at HCC in July 2021 following over 15 years in higher education. 'Throughout her time at HCC, Dr. Mathis has exemplified the core values of our institution and played a key role in advancing our strategic goals. Her leadership, vision, and commitment have left a lasting impact on our community,' said President Timmons. A Hartford native, Mathis earned several degrees, a bachelor's degree in biology from Eastern Connecticut State University, a master's degree in biomedical sciences from Quinnipiac University, and a doctorate in Educational Leadership from the University of Hartford. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
South Wales Argus
a day ago
- Business
- South Wales Argus
HCC survey to shape future of Welsh red meat industry
The survey, which went live on May 20, aims to gather views from levy payers to inform HCC's new Vision 2030. The document will set the organisation's priorities for the next four years. HCC chief executive José Peralta said: "The survey is the next step to gather industry views on the industry's challenges and priorities, and what HCC can do to support it." Mr Peralta also emphasised the importance of stakeholder contributions from across Wales to ensure HCC is fully informed of the industry's challenges. The survey is part of a broader engagement plan for 2025, which includes meetings and HCC attendance at livestock markets and events. The first of these was held in the NSA Welsh Sheep event at Tregoyd Farm, Brecon on May 21. The survey will remain open until July 25 on the HCC website.
Yahoo
2 days ago
- Business
- Yahoo
Holyoke Community College to offer free course in AI essentials
HOLYOKE, Mass. (WWLP) – Holyoke Community College (HCC) is offering a free 12-week training course this summer on artificial intelligence. The program, titled 'AI Essentials,' is being launched in partnership with the non-profit organization CanCode Communities. The class will run on Tuesdays and Thursdays from June 24 to September 11 from 5:45 p.m. to 8:45 p.m. These western Massachusetts cities awarded funding to boost protection against cyberattacks Participants will get the opportunity to learn about the practical applications of AI, such as prompt engineering, tokenization, model structures, ethics, and more. They will also learn to use leveraging tools, including Google AI Studio, n8n, and OpenWebUI, to delve further into how AI models are built and trained for real-world use. 'Along the way, participants will gain valuable professional development experience, enhancing their technical skills and problem-solving abilities,' said Arvard Lingham, HCC Executive Director of Community Education and Corporate Training. The class is free to eligible Massachusetts residents, with tuition assistance available for qualified residents age 18 and older. Limited seats are offered, and laptops and WiFi hotspots for Internet access will be provided for students who require them. This program is being funded by the Western Mass Alliance for Digital Equity. Those interested in signing up for the class can email admissions@ or visit WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 days ago
- Business
- Yahoo
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body's immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors. CancerVax's novel platform uses engineered lipid nanoparticles to detect and mark only cancer cells for destruction by the immune system. The nanoparticles use a 2-step detection mechanism to precisely target cancer cells, while leaving healthy cells unharmed. The nanoparticles first target cells with specific surface proteins ('Marker1'), then release proprietary Smart mRNAs that are activated only in the presence of cancer-specific signatures ('Marker2'). Once activated, the mRNA forces cancer cells to express proteins associated with well-immunized diseases like measles, effectively tricking the immune system into killing cancer cells as if they were common diseases. The Company previously announced that it was targeting pancreatic ductal adenocarcinoma (PDAC) in its preclinical program. After extensive research and AI-driven analysis, the Company's scientific team has discovered a very distinct Marker2 signature for a group of rare liver cancers. These tumors have stem cell characteristics, making them more aggressive and less responsive to traditional therapies. By taking advantage of the distinct Marker2 signature, CancerVax believes it can overcome the severe unmet clinical need for these cancer patients and can more quickly validate the universality of its platform. The Company's preclinical cancer indications will now be expanded to three (3) cancer types: PDAC, rare HCC and ICC. Dr. Adam Grant, Principal Scientist of CancerVax said, "When we first identified these subsets of liver cancers with this distinct Marker2 signature, I couldn't believe it. It was amazing to come across a patient population that has a high unmet clinical need and is uniquely suited to validate our technology. Of course, we expect that our platform will work on many different cancer types but the unique genetic signatures in these rare liver cancers make them a no-brainer for us to target. This precision-based discovery is what every computational biologist dreams of and I'm beyond excited to have the opportunity to help provide relief for these patients with severely poor outcomes. Dr. George Katibah, Chief Scientific Officer of CancerVax said, "The results from our AI data analytics are really striking. This particular cancer biology leads to not one but a group of rare liver cancers for which there are limited treatments. Our team has uncovered this novel cancer stem cell biology using advanced computational techniques showing that these tumors' underlying biology can be targeted by the CancerVax approach. These results demonstrate the flexibility of our platform and how we can swap out Marker1 and Marker2 to attack other cancers with a precision medicine approach. The next steps include creating new nanoparticles for these new cancer indications and to perform in vitro and in vivo studies to evaluate efficacy and safety.' The Company's universal cancer treatment platform is architected in such a way that off-the-shelf injections can be created by changing the Marker1 and Marker2 combination to target different cancer types. This approach allows for the Company's immunotherapies to be broadly available when a patient is diagnosed and needs to be treated immediately. These injections are more like 'off-the-shelf' flu shots, rather than complex treatment procedures. About CancerVax CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot -- a better way to fight cancer. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact:CancerVax, (805) 356-1810Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
04-06-2025
- Business
- Time of India
New Heritage Conservation Committee orders audit of past restoration approvals in India's first UNESCO World Heritage City of Ahmedabad
Ahmedabad: In a decisive move to preserve the historic character of Ahmedabad, India's first UNESCO World Heritage City, the newly restructured Heritage Conservation Committee has hit pause on nearly 40 heritage restoration approvals that the previous panel issued earlier this year. Tired of too many ads? go ad free now The committee flagged irregularities in two key meetings held this year, where most members were municipal staff and not officially appointed conservation experts. A subcommittee will now review the building permissions across five wards. The HCC is a key body responsible for recommending conservation, restoration, and adaptive reuse of heritage properties within the Unesco-inscribed World Heritage City zone. This decision came during the 95th HCC meeting held on May 20, and concerns actions taken in the 93rd and 94th meetings conducted on Jan 22 and Feb 12 earlier this year. According to a senior official in the Ahmedabad Municipal Corporation (AMC), the legitimacy of those two earlier meetings has been questioned. A senior municipal official told TOI, "A majority of the members present during the two HCC meetings were municipal employees, not state-appointed HCC members. So, the recommendations from the meetings will be examined by a newly formed subcommittee." These decisions involve permissions for 39 buildings across five wards in the Walled City. Most of these applications, 19, are for residential and commercial properties in Khadia, including areas such as Sankdi Sheri, Fatasha ni Pol, Sevaka ni Wadi, Akasheth Kuva ni Pol (including Dakorewali Khadki), Ranchoddji Mandir, Raipur Chakla to Sarangpur Chakla, and Verai Pada ni Pol. Tired of too many ads? go ad free now Additionally, there are five applications from Dariapur ward (including Dandigara ni Pol and Jadabhagat ni Pol), eight from Kalupur ward (covering Gosaji Maharaja ni Pol, Raja Mehta ni Pol, Haji Patel ni Pol, Gheekanta Road, and Chippa Pol), five from Jamalpur ward, and one from Raikhad ward. The AMC official further said, "It was the arbitrariness of the decision-making process that led the now municipal commissioner-led HCC to form a subcommittee to review all 39 decisions."
